ICON, a global provider of drug development solutions and services has acquired MolecularMD, a molecular diagnostic specialty laboratory that enables the development and commercialization of precision medicines in oncology. The acquisition of MolecularMD’s extensive scientific and clinical biomarker experience expands the ICON’s capabilities in molecular diagnostic testing and also adds expanded testing platforms, including next-generation sequencing and immunohistochemistry, to ICON’s
Read More
Precision Medicine Oncology | Molecular Profiling | News, Analysis, Insights
Proteus Launches Digital Cancer Chemotherapy Pill Program for Cancer Patients
Proteus Digital Health, Inc., Fairview Health Services, and the University of Minnesota Health announced that for the first time cancer patients are using digital oncology medicines to support treatment regimens and improve outcomes. This advancement helps patients complete oral chemotherapy cycles while oncologists gain new insights into their patients’ treatment progress and overall health status. Proteus, Fairview, and the University of Minnesota Health unveiled the care model for digital
Read More
Syapse to Utilize NCCN Biomarkers Compendium for More Personalized Care
New partnership between National Comprehensive Cancer Network and Syapse will augment health information technology around cancer care. The National Comprehensive Cancer Network(NCCN) announced a new agreement with Syapse, a precision medicine company, to expand the use of best practices in precision medicine when treating people with cancer. Syapse delivers solutions for scaling enterprise precision oncology programs. For Syapse, the data contained in theNCCN Biomarkers Compendium will
Read More
Proscia Raises $8M for AI-Enhanced Digital Pathology for Cancer Diagnosis
Proscia, a Philadelphia-based digital pathology platform has raised $8.3 million in Series A funding led by Boston-based Flybridge Capital Partners with participation from Emerald Development Managers, Fusion Fund, Razor’s Edge Ventures, and RobinHood Ventures.The startup plans to utilize the Series A funding to fuel the development and commercialization of new, clinical AI-enabled workflows targeting high-volume, high-impact cancers, the first of which will be available later this year. In
Read More
Roche Acquires Rest of Foundational Medicine for $2.4B to Enhance Precision Medicine
Roche, today announced it has acquire all of the outstanding shares in Foundation Medicine that is not already owned by Roche and its affiliates for $2.4B, representing $137 per share. Together, the companies will leverage expertise in genomics and molecular information to enhance the development of perdsonalized medicines and care for patients with cancer.Foundation Medicine, based in Cambridge, Massachusetts, is a market leading molecular information company dedicated to a transformation in
Read More
Syapse Precision Medicine Council Launches to Advance Precision Oncology Adoption
Syapse, a San Francisco, CA-based precision medicine company, announced today the formation of the Syapse Precision Medicine Council, a group of oncology, operations, and research leaders from health systems dedicated to advancing precision oncology adoption through sharing best practices.Inaugural members include Henry Ford Health System, Catholic Health Initiatives and Dignity Health (the Precision Medicine Alliance), Providence St. Joseph Health, Aurora Health Care, and the University of
Read More
Fitango Health Unveils Oncology Precision Medicine App for Providers to Achieve Value-Based Goals
Fitango Health, a provider of integrated care management and patient engagement software, is announcing a transformative new solution, called Fitango Oncology. Fitango Health's innovative application allows healthcare providers to achieve value-based goals through end-to-end engagement spanning the continuum of care.This end-to-end solution is the first of its kind for both oncology and chronic care to integrate decision-support, treatment communication, along with enabling and engaging both
Read More
Precision Health AI Launches Oncology AI Platform Driven by EMR Dataset
Precision Health AI, a healthcare technology company focused on the application of artificial intelligence to cancer care, today announced the launch of the Eureka Health Oncology AI Platform. The 60+ set of pre-trained AI solution modules will utilize Precision Health AI’s proprietary data to predict a patient’s cancer stage, treatment journey, flow through the healthcare system and survival rate.Driving the new Eureka Health Oncology AI platform is Precision Health AI’s deep, longitudinal
Read More
Medidata, Syapse Partner to Democratize Access to Oncology Clinical Trials
Medidata, a provider of cloud-based technology and data analytics for clinical research, and Syapse, a precision medicine solutions provider, have announced a new partnership to transform oncology clinical trials for the age of precision medicine. As part of the new partnership, Medidata and Syapse will jointly develop a portfolio of solutions to make it easier for cancer patients to access potentially life-saving clinical trials,Partnership DetailsThe partnership will initially build products
Read More
Syapse Expands Precision Medicine to Asia Through Partnership With Health System
Syapse, a precision medicine company, announced today it is expanding to Asia through new partnerships with Seoul National University Hospital (SNUH), the premier hospital in Korea, and Megazone, a cloud-specialized IT company.Syapse and SNUH are launching a precision oncology program to improve cancer care in Korea, with the support of Megazone’s innovative cloud services. SNUH, one of the largest health systems in South Korea, is the first health system outside the U.S. to use the Syapse
Read More
